Company news
Xizang Weixinkang Pharmaceutical Co., Ltd. Class A (SSE:603676) news
Xizang Weixinkang Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 11, 2026: "XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement…
Press releases & updates
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on Receipt of the Drug Registration Certificate for Water-soluble Vitamin for Injection by a Subsidiary
September 10, 2026
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on Receipt of the Approval Notice for Supplementary Application for Potassium Aspartate Injection by a Subsidiary
August 31, 2026
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 27, 2026
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on the Subsidiary's Acquisition of the Drug Registration Certificate for Multivitamin Injection (12)
August 7, 2026
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on Participation in Subscription of Private Equity Fund Shares
August 3, 2026
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on the Termination of the Exclusive License Agreement
July 17, 2026
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on the Subsidiary's Obtaining the Drug Registration Certificate for Compound Potassium Hydrogen Phosphate Injection
July 10, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 22, 2026
Announcement on Participation in Subscription of Private Equity Fund Shares
May 27, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 14, 2026
Announcement on the Provision of Online Voting Reminder Service for the General Meeting
April 23, 2026
Announcement on Subsidiary Obtaining Drug Registration Certificate for Isavuconazole for Injection
March 6, 2026
Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
December 3, 2025
西藏卫信康医药股份有限公司2025年前三季度权益分派实施公告
November 18, 2025
Announcement on Resolutions of the 4th Meeting of the 4th Board of Directors
October 29, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 12, 2025
Announcement on Resolutions of the 3rd Meeting of the 4th Board of Directors
August 27, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 4, 2025
Announcement on Obtaining Government Subsidies
June 30, 2025
Announcement on the Company's Collaborative Products Passing Consistency Evaluation of Generic Drug Quality and Efficacy
June 24, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 4, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 16, 2025
Announcement on Resolution of the 2nd Meeting of the 4th Board of Directors
May 15, 2025
Announcement on Withdrawal of Drug Registration Application by Subsidiary
May 9, 2025
Announcement on Resolution of the 1st Meeting of the 4th Board of Directors
April 30, 2025
Announcement on Subsidiary Obtaining Drug Registration Certificate for Compound Amino Acid Injection (18AA-IX)
April 27, 2025
2024 Annual Report
April 25, 2025
Announcement on Passing the Consistency Evaluation of Generic Drug Quality and Efficacy for Subsidiary's Drug
April 22, 2025
Announcement on Postponement of the 1st Extraordinary General Meeting in 2025
April 14, 2025
Announcement on Resolutions of the 13th Meeting of the 3rd Board of Directors
April 2, 2025
Announcement on Subsidiary Obtaining Drug Registration Certificate for Compound Amino Acid Injection (18AA-VII)
February 25, 2025
Announcement on Obtaining Drug Registration Certificate for Acetylcysteine Solution for Inhalation by the Subsidiaries
February 13, 2025
Announcement on Completion of Industrial and Commercial Change Registration by Wholly-owned Subsidiary
January 23, 2025
Rectification Report on the Decision of Administrative Supervision Measures by Xizang Office of China Securities Regulatory Commission
January 3, 2025
Announcement on the Company and Relevant Responsible Persons Receiving Decision on Administrative Supervision Measures from Xizang Office of China Securities Regulatory Commission
December 24, 2024
Indicative Announcement on Postponing the Election of Board of Directors and Board of Supervisors
December 20, 2024
Announcement on Implementation Results of Share Repurchase and Share Changes
December 19, 2024
Announcement on Passing the Consistency Evaluation of Generic Drug Quality and Efficacy for Subsidiary Drugs
December 2, 2024
Announcement on the Renewal of the Wholly-owned Subsidiary's Drug in the Catalogue of Drugs for Basic National Medical Insurance (2024)
November 29, 2024
Announcement on Initially Repurchasing Shares through Call Auction
November 25, 2024
Announcement on Withdrawal of Drug Registration Application by the Subsidiary
November 14, 2024
Announcement on Implementation of Dividend Distribution for Q1-Q3 2024
November 5, 2024
Announcement on Progress in Repurchasing Shares
November 4, 2024
Announcement on Resolution of the 11th Meeting of the 3rd Board of Supervisors
October 28, 2024
Announcement on Signing Exclusive License Agreement
September 27, 2024
Announcement on Expiration of Shareholding Reduction by Directors and Senior Management Members through Call Auction and the Result of Unreduced Shares
September 12, 2024
Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary
September 6, 2024